Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2659 | Observational (registry) Wiki | 0.71 |
| drug3906 | Taste and olfactory function evaluation Wiki | 0.71 |
| drug3600 | Serum testing Wiki | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007239 | Infection NIH | 0.03 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| D018352 | Coronavirus Infections NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.
Description: Ratio of olfactory sensory cells in the nasal cytological sample
Measure: Molecular and cellular defects in olfactory epithelium Time: 30 monthsDescription: Multiple measurements will be analyzed to characterize the immune and inflamatory status of the olfactory mucosa (presence of infiltrated immune cells, activation state of the immune cells in the epithelium, cytokine and interleukin level)
Measure: Biological mechanisms involved in the pathogenesis of the disease Time: 30 monthsDescription: Demographic variables (sex, age, blood type), risk factors (tobacco, overweight, diabetes, rhinosinusitis disease, respiratory allergy)
Measure: Epidemiological characteristics Time: 30 monthsDescription: Self-questionnaire taste and smell survey (TTS)
Measure: Olfactory and taste dysfunction Time: 30 monthsDescription: Visual analogue scale (VAS) (units from 0 normal perception to 100 no perception)
Measure: Olfactory and taste dysfunction Time: 30 monthsThe main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by assessing serological responses to SARS-CoV-2 in symptomatic and asymptomatic HCWs over time and 3) to improve the assessment of the immune response and its protective effect as well as the assessment of infectivity of affected HCWs and 4) to evaluate the value and significance of antibody formation and serological antibody tests and 5) to be able to evaluate possible future preventive and / or therapeutic approaches against SARS-CoV-2
Description: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 1 yearDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 1 yearDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 2 yearsDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 3 yearsDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 4 yearsDescription: Anti-SARS-COV2 S protein IgG ELISA
Measure: Number of people with detectable antibodies to SARS-COV2 Time: 5 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 2 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 3 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 4 yearsDescription: SARS-COV2 PCR
Measure: Number of people with detectable SARS-COV2 nucleic acid Time: 5 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports